Document is current
Any future updates will be listed below
-
Authors
Santamaria, Xavier https://orcid.org/0000-0002-5689-6200
Pardo-Figuerez, María
González-Fernández, Javier https://orcid.org/0000-0002-9625-5264
Querol, Sergi
Rodríguez, Luciano
Valcárcel, David
González, Carla
Fernandez, Estefanía
Amorós, Diego https://orcid.org/0000-0003-2035-6189
Robles, Michael
Granados-Aparici, Sofia https://orcid.org/0000-0003-4448-3254
Zuñiga, Sheila https://orcid.org/0000-0002-3272-7605
Martinez, Francisco https://orcid.org/0009-0002-0760-8206
Valbuena, Diana https://orcid.org/0000-0002-0742-3669
Gómez, Carlos
Herrero, Julio
Aurell, Ramon
Torrent, Juan José
Vilella, Felipe https://orcid.org/0000-0002-0039-9846
Volkov, Petr
Raga, Francisco
Noguera, Rosa https://orcid.org/0000-0003-4546-7459
Taylor, Hugh S.
Simon, Carlos https://orcid.org/0000-0003-0902-9531
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 10 December 2025
First Online: 2 January 2026
Competing interests
: C.S. & X.S. are founders, shareholders of Asherman Therapy S.L. and inventors of patents granted in Europe, Australia, Canada, Japan, Russian Federation, Mexico, and the US derived from PCT application PCT/IB2015/001715. MPF and EF are employees of Asherman Therapy SL. MPF has been awarded a Torres Quevedo Grant (PTQ2022-012376). CS has received consulting fees from Vitrolife. RA, SQ, CG, JT and JH have no potential conflict of interest with this therapy nor Asherman Therapy SL. DV has received consulting fees, honoraria for lectures or educational events from Amgen, BMS/Celgene, Kite/Gilead, Novartis, Sanofi, Grifols, Jad Pharmaceuticals, MDS, Pfizer, Sobe, Astellas, Jansen and Gebro. SG is employed by Ciberonc (CB16/12/00484). This study was also partially supported by research grants PROMETEO/2018/161 from the Valencia Government, IDI-20201142 CDTI from the Centro Desarrollo Tecnológico e Industrial (CDTI, Spain) and the KY Cha Award for Stem Cell Technologies of the American Society of Reproductive Medicine (ASRM) and was partly supported by FIS (Institute of Health Carlos III, Madrid/ERDF, PI20/01107) and CIBERONC (CB16/12/00484).
